Plasma Kallikrein

• 

  Subject Areas on Research

  • Phase 1 Dose-Escalation Study of Plasma Kallikrein Inhibitor THR-149 for the Treatment of Diabetic Macular Edema. 
  • Plasma kallikrein predicts primary graft dysfunction after heart transplant.